Delayed
Bombay S.E.
04:54:50 2024-05-08 am EDT
|
5-day change
|
1st Jan Change
|
48.29
INR
|
+11.94%
|
|
+4.64%
|
+27.01%
|
Fiscal Period: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
815.4
|
1,095
|
1,460
|
1,353
|
2,675
|
1,572
|
Enterprise Value (EV)
1 |
1,112
|
1,352
|
1,640
|
1,485
|
2,687
|
1,739
|
P/E ratio
|
63.8
x
|
26
x
|
10.4
x
|
4.61
x
|
5.67
x
|
14.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.65
x
|
0.72
x
|
1.09
x
|
0.82
x
|
1.35
x
|
0.91
x
|
EV / Revenue
|
0.89
x
|
0.89
x
|
1.23
x
|
0.9
x
|
1.36
x
|
1.01
x
|
EV / EBITDA
|
-10.7
x
|
14.2
x
|
345
x
|
21
x
|
9.54
x
|
14.3
x
|
EV / FCF
|
-7.08
x
|
14.7
x
|
-5.79
x
|
-10.1
x
|
-11.3
x
|
-8.82
x
|
FCF Yield
|
-14.1%
|
6.79%
|
-17.3%
|
-9.88%
|
-8.86%
|
-11.3%
|
Price to Book
|
3.07
x
|
3.58
x
|
3.26
x
|
1.83
x
|
2.23
x
|
1.2
x
|
Nbr of stocks (in thousands)
|
76,633
|
76,633
|
76,633
|
76,633
|
76,633
|
76,633
|
Reference price
2 |
10.64
|
14.29
|
19.05
|
17.65
|
34.90
|
20.51
|
Announcement Date
|
8/14/18
|
8/7/19
|
9/8/20
|
9/1/21
|
8/30/22
|
9/6/23
|
Fiscal Period: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,250
|
1,519
|
1,335
|
1,652
|
1,975
|
1,721
|
EBITDA
1 |
-103.8
|
95.22
|
4.76
|
70.74
|
281.8
|
121.3
|
EBIT
1 |
-123.9
|
74.8
|
-14.41
|
52.84
|
264.7
|
100.4
|
Operating Margin
|
-9.91%
|
4.93%
|
-1.08%
|
3.2%
|
13.4%
|
5.84%
|
Earnings before Tax (EBT)
1 |
79.64
|
82.13
|
149.4
|
325.4
|
541.9
|
148.3
|
Net income
1 |
12.77
|
42.49
|
140.6
|
293.6
|
472.2
|
111
|
Net margin
|
1.02%
|
2.8%
|
10.53%
|
17.77%
|
23.91%
|
6.45%
|
EPS
2 |
0.1666
|
0.5500
|
1.830
|
3.830
|
6.160
|
1.449
|
Free Cash Flow
1 |
-157.1
|
91.79
|
-283.3
|
-146.6
|
-238
|
-197.1
|
FCF margin
|
-12.57%
|
6.04%
|
-21.22%
|
-8.88%
|
-12.05%
|
-11.45%
|
FCF Conversion (EBITDA)
|
-
|
96.4%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
216.02%
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/14/18
|
8/7/19
|
9/8/20
|
9/1/21
|
8/30/22
|
9/6/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
297
|
257
|
180
|
132
|
12.8
|
167
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-2.862
x
|
2.7
x
|
37.81
x
|
1.866
x
|
0.0456
x
|
1.379
x
|
Free Cash Flow
1 |
-157
|
91.8
|
-283
|
-147
|
-238
|
-197
|
ROE (net income / shareholders' equity)
|
4.93%
|
14.9%
|
37.3%
|
49.5%
|
48.7%
|
8.85%
|
ROA (Net income/ Total Assets)
|
-4.26%
|
2.24%
|
-0.45%
|
1.67%
|
7.51%
|
2.64%
|
Assets
1 |
-300
|
1,898
|
-31,297
|
17,622
|
6,288
|
4,211
|
Book Value Per Share
2 |
3.460
|
4.000
|
5.840
|
9.640
|
15.60
|
17.10
|
Cash Flow per Share
2 |
1.760
|
2.220
|
1.670
|
1.920
|
1.580
|
1.320
|
Capex
1 |
116
|
104
|
38.1
|
24.6
|
157
|
207
|
Capex / Sales
|
9.24%
|
6.84%
|
2.86%
|
1.49%
|
7.95%
|
12.01%
|
Announcement Date
|
8/14/18
|
8/7/19
|
9/8/20
|
9/1/21
|
8/30/22
|
9/6/23
|
|
1st Jan change
|
Capi.
|
---|
| +27.01% | 39.62M | | +20.41% | 43.57B | | +20.70% | 22.7B | | +16.08% | 14.32B | | +11.23% | 13.42B | | +45.02% | 11.83B | | -8.84% | 6.98B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +12.33% | 5.51B |
Generic Pharmaceuticals
|